Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 27, 2023

SELL
$103.46 - $126.29 $45,522 - $55,567
-440 Reduced 3.47%
12,243 $1.31 Million
Q4 2022

Jan 23, 2023

BUY
$36.06 - $117.21 $457,348 - $1.49 Million
12,683 New
12,683 $0

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Moody Aldrich Partners LLC Portfolio

Follow Moody Aldrich Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Aldrich Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Aldrich Partners LLC with notifications on news.